FP
Nice reply, your points are good ones. Maybe the SP is just a measure of confidence in which case the last few days have shown that there's a lot of people more confident than I am. In the minority here, still a holder though.
To be fair, the potential is ridiculous and a relatively modest outlay could see the sort of return that doesn't come along too often. Appetite for risk and all that.
Regards numbers, I'll feel more confident once this 1b is successfully completed - a mix of dosages plus short and long term monitoring will do nicely, especially the long term.
True, the SP might well be out of sight by then, but I don't want to be seduced by the potential here and go crazy accumulating, so much potential . . . Happy to sit on what I've got and see what happens. If the Vienna meetup was called for happy purpose then the SP could be off and away before the end of the trial(month?), we can only hope. My hope is that long term monitoring has revealed an ongoing reduction in the tumors.
Also true, I am ignoring the beagle cardio testing and concentrating on clinical trials. It's a human numbers thing. Not large enough yet for me to be as confident as you are.
I look at what's happened with Herceptin as, although they are synthetic, they're still a bunch of antibodies targeting the same receptor as Her-vaxx. Admittedly, the incidence of cardio issues seems to increase the longer Herceptin is administered and these Her-vaxx trials are relatively short compared to an ongoing regimen of Herceptin + chemo.
You've obviously put a lot of research into this. Have you ever seen anything discussing how a long term immune response might work regards antibodies binding to HER-2 on healthy cells? Is it an issue? Is the normal level of HER-2 expression enough to keep the body pumping out antibodies after the cancer is done? I've probably missed something somewhere.
cheers
dyor etc etc
Add to My Watchlist
What is My Watchlist?
